ASCO Value Framework Presents ‘Net Health Benefit’ Score For Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
The framework does not integrate cost into the benefit score calculated for drugs because ASCO felt this would detract from a focus on treatment performance.
You may also be interested in...
Medicaid ‘Price Verification’ Audit Proposal Aims To Promote Cell, Gene Therapy Rebate Concessions
CMS proposed rule impact may be ‘modest’ but is framed as ensuring patient access to cutting edge treatments by helping to control Medicaid spending. Biden administration initiative also aims to address misclassification of brand drugs, duplicative 340B discounts, and PBM spread pricing.
Medicare Unlikely To Embrace Cost Effectiveness In Early Price Negotiations – ICER’s Pearson
The government’s rush to stand up the negotiation program by the fall likely means an approach to cost effectiveness will be left out of at least the first cycle. But it could be incorporated over time.
Lilly’s Dosing Scheme For Donanemab In Alzheimer’s And Treatment Cost Effectiveness
Firm’s aggressive approach to amyloid plaque removal means a shorter duration of treatment and potentially lower costs.